TY - JOUR
T1 - TGF-β signaling and the role of inhibitory smads in non-small cell lung cancer
AU - Jeon, Hyo Sung
AU - Jen, Jin
N1 - Funding Information:
Supported in part by a grant from the national R&D Program for Cancer Control Ministry of Health & Welfare, Republic of Korea (0720550-2) and the Brain Korea 21 Project (to H.S.J.) and by Research Funds from the Mayo Cancer Center and the Mayo Center for Individualized Medicine (to J.J.).
PY - 2010/4
Y1 - 2010/4
N2 - The signaling pathway mediated by transforming growth factor-β (TGF-β) participates in various biologic processes, including cell growth, differentiation, angiogenesis, apoptosis, and extracellular matrix remodeling. In the context of cancer, TGF-β signaling can inhibit tumor growth in early-stage tumors. However, in late-stage tumors, the very same pathway promotes tumor invasiveness and metastasis. This paradoxical effect is mediated through similar to mothers against decapentaplegic or Smad protein dependent and independent mechanisms and provides an opportunity for targeted cancer therapy. This review summarizes the molecular process of TGF-β signaling and the changes in inhibitory Smads that contribute to lung cancer progression. We also present current approaches for rational therapies that target the TGF-β signaling pathway in cancer.
AB - The signaling pathway mediated by transforming growth factor-β (TGF-β) participates in various biologic processes, including cell growth, differentiation, angiogenesis, apoptosis, and extracellular matrix remodeling. In the context of cancer, TGF-β signaling can inhibit tumor growth in early-stage tumors. However, in late-stage tumors, the very same pathway promotes tumor invasiveness and metastasis. This paradoxical effect is mediated through similar to mothers against decapentaplegic or Smad protein dependent and independent mechanisms and provides an opportunity for targeted cancer therapy. This review summarizes the molecular process of TGF-β signaling and the changes in inhibitory Smads that contribute to lung cancer progression. We also present current approaches for rational therapies that target the TGF-β signaling pathway in cancer.
KW - Non-small cell lung cancer survival
KW - Smads
KW - TGF-β signaling
KW - Target-based therapy
UR - http://www.scopus.com/inward/record.url?scp=77950977675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950977675&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e3181ce3afd
DO - 10.1097/JTO.0b013e3181ce3afd
M3 - Short survey
C2 - 20107423
AN - SCOPUS:77950977675
SN - 1556-0864
VL - 5
SP - 417
EP - 419
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 4
ER -